Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
Fred R. Hirsch(Tisch Hospital), Brian R. Holloway(AstraZeneca (Singapore)), Purvish M. Parikh(Tata Memorial Hospital), Alex Y. Chang(Cornell University), Dinah V. Parums(AstraZeneca (Singapore)), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Lucy Knight(AstraZeneca (Singapore)), Rafał Dziadziuszko(Gdańsk Medical University), Claire Watkins(AstraZeneca (United Kingdom)), Paul A. Bunn(University of Colorado Denver), Emma Donald(AstraZeneca (Singapore)), José Rodrigues Pereira, Wilbur A. Franklin(University of Colorado Health), Nicholas Botwood(AstraZeneca (Singapore)), Angela V. Flannery(AstraZeneca (Singapore)), Nick Thatcher(The Christie Hospital), Gillian Ellison(AstraZeneca (Singapore)), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta)
Cited by 702
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k